Focus: Lundbeck is a Danish specialty pharmaceutical company with 5,001-10,000 employees focused on CNS and neurological disorders. The company generates significant revenue from peak-stage products in epilepsy, movement disorders, and migraine.
Profile data last refreshed Yesterday · AI intelligence enriched 3w ago
No open roles listed right now. Follow Lundbeck to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Anchor product generating 36% of company revenue; peak-stage but no LOE date disclosed, suggesting extended exclusivity.
Help build intelligence for Lundbeck
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Lundbeck's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Second-largest revenue driver in movement disorders; peak-stage with stable reimbursement profile.
Monoclonal antibody for migraine; peak-stage in competitive CGRP antagonist class with expansion potential.
IV formulation with extended exclusivity to 2040; provides stable long-tail revenue in controlled indications.
Approaching loss of exclusivity; reimbursement remains at $18M but erosion risk is material.
2 discontinued, 2 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 3 crawl cycles